Article
Outlook Therapeutics To Revise Ophthalmic Bevacizumab BLA In Light Of FDA Request
Outlook Therapeutics announced today that the FDA has requested additional information in order to complete the filing of the company's BLA for LYTENAVA. LYTENAVA, or ONS-5010...
Goodwin Procter LLP




